News|Articles|December 2, 2025

2025 in Hepatology: New MASLD Therapies, HBV Updates, and More

Author(s)Hersh Shroff, MD, MPA, Zobair Younossi, MD, MPH, Wei Zhang, MD, PhD

Recent advancements in hepatology highlight new medications for metabolic dysfunction and liver diseases, promising improved patient outcomes and treatment options.

2025 has marked a clear turning point in hepatology, bringing advances that are reshaping both the scientific landscape and everyday clinical practice. After years defined by limited therapeutic options and slow-moving pipelines, this year delivered transformative progress, from the long-awaited arrival of effective pharmacologic treatments for MASLD/MASH to renewed innovation in viral hepatitis, cholestatic liver diseases, portal hypertension, and alcohol-associated liver disease.

Related to this article

September 21st, 2026

Binge Drinking and ALD, MetALD Fibrosis Risk, With Frances Lee, MD

Frances Lee, MD, on stigma's role in ALD care and why women may progress to advanced disease faster than men.

September 22nd, 2026

Stigma and Sex Differences in ALD Care, With Frances Lee, MD

Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.

September 22nd, 2026

Skin of Color Savvy: How SOCS Serves Builds Dermatology Pathways and Community Trust

SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.

September 15th, 2026

FAQ: What the New BEACON-HCC Framework Changes in HCC Treatment

BEACON-HCC offers a new approach to HCC treatment allocation, with key differences from the updated BCLC framework.

September 22nd, 2026

How the ASN's GD-C Compendium Aims to Unify Glomerular Disease Care

George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.

Andrew J. Cutler, MD Credit: Neuroscience Education Institute

September 22nd, 2026

ProACt Data Show Early Functional Gains with Adjunctive Cariprazine In MDD

Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.